Share this article
Share this article
LOS ANGELES, Feb. 19, 2021 /PRNewswire/ Normally used to providing health services in Myanmar (Burma) s conflict zones and Rohingya refugee camps in Bangladesh, the California nonprofit Community Partners International (CPI) is now helping LA County hospitals cope with the latest wave of the coronavirus disease (COVID-19) pandemic.
As of February 18, more than 3.5 million people in California have tested positive for COVID-19, and over 47,000 have died. Intensive care unit (ICU) capacity in Southern California has plummeted to 0% at times as hospitals struggle with COVID-19 patient numbers.
In January, Community Partners International teamed up with Direct Relief to provide home-based care to patients recovering from COVID-19, freeing up vital bed space to receive new patients that need intensive and emergency care.
First Cancer Early Screening Company Listed on HKEX as New Horizon Health Debuts
News provided by
Share this article
Share this article
SHANGHAI, Feb. 17, 2021 /PRNewswire/ Qiming s portfolio company New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company.
The issue price is HK$26.66 per share; the stock opens at HK$76 per share, up 185.07%, with a market cap of HK$31.764 billion. New Horizon Health public offering shares were oversubscribed for 4,133 times with over HK$850 billion committed, making it the second most oversubscribed stock in the HKEx history.
Share this article
Share this article
ROTTERDAM, Netherlands and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ Today, SkylineDx announced that it received the esteemed ISO 13485:2016 Quality Management System certificate from notified body BSI Netherlands, after their successful audit in November 2020. This internationally recognized standard of excellence is a stringent guideline for medical device manufacturers to address the regulations, responsibilities and demonstrate the commitment to the safety and quality of the developed medical devices. To achieve this certification, SkylineDx had to demonstrate consistent design, development and servicing of their molecular tests, that they are safe and effective for their intended purpose. Medical device manufacturing is one of the most regulated sectors in which significant requirements must be met, comments Dharminder Chahal, CEO SkylineDx. This external confirmation is an important milestone for SkylineDx as it validates the complianc
/CNW/ - Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE) today announced that it has entered into an agreement with Canaccord Genuity Corp. on.
Rein Piir, Senior Advisor Investor Relations, Oncopeptides AB (publ)
Telephone: +46 (0)70 853 72 92
This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on February 18, 2021.
About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the phase 3 OCEAN study. Based on the results from the HORIZON study a New Drug Application ha